𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Human sodium iodide symporter gene adjunctive radiotherapy to enhance the preventive effect of hMUC1 DNA vaccine

✍ Scribed by Yong Hyun Jeon; Yun Choi; Hyun Joo Kim; Chul Woo Kim; Jae Min Jeong; Dong Soo Lee; June-Key Chung


Book ID
102270874
Publisher
John Wiley and Sons
Year
2007
Tongue
French
Weight
334 KB
Volume
121
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

We demonstrate the use of combination therapy to overcome the limitations of cancer DNA vaccines by adding radioiodine gene therapy in an animal cancer model. We established a stable cell line (CT26/hMUC1‐hNIS‐F__luc__: CMNF) expressing the hMUC1, hNIS and F__luc__ genes using a retro‐ and lentivirus system. The survival rates (%) of CMNF cells were determined using clonogenic assays after ^131^I treatment. After i.m. immunization to 4 groups of Balb/c mice (pcDNA3.1, pcDNA3.1+^131^I, pcDNA3‐hMUC1+PBS and pcDNA3‐hMUC1+^131^I groups) with pcDNA3‐hMUC1 or pcDNA3.1 once a week for 2 weeks, 1 × 10^5^ CMNF cells were injected s.c. into the right thighs of mice in each group. Twenty‐one days after tumor transplantation, ^131^I was administered i.p. to the pcDNA3.1+^131^I and pcDNA3‐hMUC1+ ^131^I groups. Tumor progression was monitored in the 4 groups by bioluminescent and scintigraphic imaging and by taking caliper measurements. Tumor masses were extracted and weighted at 39 days post‐tumor challenge. We confirmed that CMNF cells highly express hMUC1, hNIS and F__luc__ by FACS, ^125^I uptake, and luciferase assay. The survival rates of CMNF were markedly reduced to (14.6 ± 1.5)% after ^131^I treatment compared with the survival rates of parental cells (p < 0.001). Tumor growth inhibition was significant only in the pcDNA3‐hMUC1+ ^131^I group at 39 days post challenge. Tumor masses in pcDNA3‐hMUC1+ ^131^I group were smaller than those of the other groups. This study shows that the weak preventive effects of cancer DNA vaccine can be overcome by radioiodine gene therapy utilizing sodium iodide symporter. © 2007 Wiley‐Liss, Inc.